Lumida
/NVCR
⌘K
Novocure Ltd

Novocure Ltd

NVCR
$15.92USD↓-3.05%-0.50 today

MARKET CAP

1.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$16 – $17

52W RANGE

$10
$19

AI Summary

Stalk
Sell NowHigh

NVCR remains in a Stage 4 decline, confirmed by persistent lower highs and lower lows under downtrending EMAs. The active Lower Highs & Lower Lows pattern indicates supply dominance and keeps the medium-term bias bearish. Price recently rallied into declining EMAs and was rejected, signaling fresh selling pressure. Short-term timing favors initiating bearish execution now into the EMA resistance zone, with failure to break above reinforcing continued downside potential.

  • ↑168 Optune Pax prescriptions and 90 active patients in first month
  • ↑Q1 net revenue $174M (+12% YoY), Germany added $2.5M
  • ↓Negative earnings yield and weak profitability factors signal poor returns
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Novocure Limited (NASDAQ: NVCR) is a leading biotechnology company specializing in innovative therapies for cancer treatment through its proprietary Tumor Treating Fields (TTFields) technology. The company primarily targets aggressive cancers such as glioblastoma multiforme (GBM) and pancreatic cancer. Recent developments, including regulatory achievements and product launches, position Novocure as a multi-indication oncology firm, focused on expanding its role within a rapidly evolving therapeutic landscape.

Bull says

  • ↑168 Optune Pax prescriptions and 90 active patients in first month
  • ↑Q1 net revenue $174M (+12% YoY), Germany added $2.5M
  • ↑Phase 2 PANOVA-4 trial shows 74% disease control rate
  • ↑FY 2026 revenue guidance $690–710M; adjusted EBITDA near breakeven
  • ↑13F ownership score indicates strong institutional interest
  • ↑Gross margin improved to 78% from 75% YoY

Bear says

  • ↓Negative earnings yield and weak profitability factors signal poor returns
  • ↓NSCLC Optune uptake slower than expected; adoption curve unclear
  • ↓Q1 net loss $71M vs $34M year-ago; R&D spend up 8% to $58M
  • ↓Medicare and FDA coverage may take 1–2 years, delaying US sales
  • ↓High share volatility (3.08) and small Size factor indicate valuation risk
  • ↓Negative momentum and growth factors underscore investor skepticism

Investment themes with NVCR

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK
Demographics: Elderly Care↓ -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026bullish

Transcript signals

Bull points

  • We are off to a strong start to the year, with 9% year-over-year growth in active patients globally.
  • We saw our strongest growth in Japan, Germany, and France, which contributed 20%, 12%, and 9% year-over-year active patient growth, respectively.
  • Our global market segment also had an outstanding quarter with 17% active patient growth, driven by a promising launch in Spain.

Bear points

  • G&A costs in the quarter were $86 million, up 92% from the same period last year. As we mentioned last quarter, we incurred a $43 million share-based compensation charge triggered by the approval of OptumPax.
  • Our net loss for the quarter was $71 million compared to $34 million in Q1 2025. Excluding the one-time share-based compensation expense, net loss was $28 million.
Read full transcript analysis ›